兔肺VX2鳞癌移植瘤射频消融后残存肿瘤ERCC1表达的变化

BACKGROUND AND OBJECTIVE: Residual carcinoma cells play an important role in the result of radiofrequency ablation (RFA) of pulmonary malignancies, and Platinum-based adjuvant chemotherapy is one of the important treatment regimen to reduce residual carcinoma cells after RFA. ERCC1 (excision repair cross-complementation group 1) is an important factor affecting Platinum-based chemotherapy effects. Residual carcinoma cells exhibit some changes of their features after RFA; however, there is no report about the change of their ERCC1 expression by now. This study focused on the change of ERCC1 expression in residual VX2 squamous carcinoma cells in rabbit lung after RFA. METHODS: The model of VX2 squamous carcinoma in rabbit lung was established by injection of tissue block suspension. Fifty-eight New Zealand White rabbits with VX2 squamous carcinoma were randomly devided into the control group (n=10) and the RFA group (n=48). During the RFA procedure in these models, residual carcinoma cells were achieved by controlling the range of electrode expanding, power output and treatment time. At different points of time, the positive rates of ERCC1 expression in residual carcinoma were detected by immunohistochemistry. RESULTS: Comparing with the control group, the positive rate of ERCC1 expression in residual carcinoma in RFA group increases transiently within 1 d to 5 d (53.7%±1.6% & 32.9%±2.5%), and 5 d later, it decline to the level of the control group. CONCLUSION: The ERCC1 expression of residual pulmonary carcinoma increase within 5 d after RFA. Thus platinum-based adjuvant chemotherapy may be ineffective in this period.